Mizuho analyst Anthony Petrone lowered the firm’s price target on ResMed (RMD) to $265 from $280 and keeps an Outperform rating on the shares as part of a Q1 preview for the medical devices and diagnostics group. The firm views tariffs, China exposure, and the latest procedure outlook as the key themes heading into the quarter. It cut numbers preemptively.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- Resmed’s Strong Financial Performance and Strategic Growth Drive Buy Rating
- Positive Outlook for Resmed Inc: Buy Rating Despite Short-Term Challenges
- ResMed placed on ‘downside 90-day catalyst watch’ at Citi
- ResMed announces availability of home sleep apnea test NightOwl
- ResMed price target lowered to $280 from $290 at BofA